ArticleCancer diagnosis & prognosis
Impact of Pre-treatment Proteinuria Progression on the Risk of Increased Proteinuria During Ramucirumab Therapy.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Ramucirumab (RAM)-based treatment is often discontinued if proteinuria levels rise to 2+ or higher (≥2+) after treatment initiation. Several risk factors contributing to an increase in ≥2+ proteinuria during RAM-based treatment have been identified. However, the impact of pre-treatment changes on proteinuria fluctuations following RAM-based treatment initiation remains unclear. Patients and Methods: This retrospective study included patients with gastric cancer who received RAM-based therapy following prior treatment with platinum-based chemotherapy at Gifu Prefectural General Medical Center between August 2015 and December 2021. Kaplan-Meier estimates were used to evaluate the incidence of ≥2+ proteinuria after initiating RAM-based treatment, based on the aggravating levels of proteinuria before initiating RAM-based treatment. Results: This study included 62 cases. The patients were divided into two groups: 14 with ≥2+ proteinuria after initiating RAM-based treatment (severe group) and 48 patients with <1 proteinuria (control group). The severe group had a higher proportion of patients presenting with trace proteinuria, Conclusion: In addition to previously reported risk factors, aggravating proteinuria within six months before initiating RAM-based treatment appears to influence post-treatment proteinuria outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.